Cerulean Pharma’s (CERU) Market Perform Rating Reiterated at Leerink Swann
Cerulean Pharma Inc. (NASDAQ:CERU)‘s stock had its “market perform” rating restated by Leerink Swann in a research note issued on Wednesday.
Other equities research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Cerulean Pharma from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Wednesday, October 5th. Canaccord Genuity reaffirmed a “buy” rating and set a $20.00 price target (down from $29.00) on shares of Cerulean Pharma in a report on Sunday, August 21st. Roth Capital reaffirmed a “buy” rating and set a $2.50 price target (down from $9.00) on shares of Cerulean Pharma in a report on Thursday, August 18th. Janney Montgomery Scott lowered shares of Cerulean Pharma from a “buy” rating to a “neutral” rating in a report on Thursday, August 18th. Finally, Wedbush lowered shares of Cerulean Pharma from an “outperform” rating to a “neutral” rating in a report on Thursday, August 18th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $7.78.
Shares of Cerulean Pharma (NASDAQ:CERU) traded up 51.146% during midday trading on Wednesday, hitting $1.029. 13,578,546 shares of the stock were exchanged. The company’s market cap is $28.18 million. Cerulean Pharma has a 12-month low of $0.67 and a 12-month high of $4.33. The firm has a 50-day moving average price of $0.96 and a 200-day moving average price of $2.14.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/cerulean-pharmas-ceru-market-perform-rating-reiterated-at-leerink-swann.html
Cerulean Pharma (NASDAQ:CERU) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.08. On average, equities analysts predict that Cerulean Pharma will post ($1.58) EPS for the current year.
A hedge fund recently raised its stake in Cerulean Pharma stock. Bridgeway Capital Management Inc. raised its position in Cerulean Pharma Inc. (NASDAQ:CERU) by 97.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 202,623 shares of the company’s stock after buying an additional 100,000 shares during the period. Bridgeway Capital Management Inc. owned 0.74% of Cerulean Pharma worth $430,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 33.19% of the company’s stock.
About Cerulean Pharma
Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.